logo
  Join        Login             Stock Quote

Boston Scientific (BSX) to Buy Vessix Vascular For $425M

 November 08, 2012 11:59 AM
 


(By Balaseshan) Boston Scientific Corp. (NYSE: BSX) said it is extending its reach into the strategically critical renal denervation market by agreeing to acquire Laguna Hills, California-based privately-held Vessix Vascular Inc. for $425 million.

The agreement calls for an upfront payment of $125 million, plus additional clinical- and sales-based milestones aggregating a maximum of $300 million over the period between 2013 and 2017.

Boston Scientific currently expects the net impact of this transaction on adjusted earnings per share to be immaterial for years 2013 and 2014 and break-even to accretive thereafter, and more dilutive on a GAAP basis as a result of acquisition-related net charges and amortization, which will be determined during the fourth quarter.

[Related -Stock Upgrades And Downgrades: BA, BSX, CVC, LTD, MDR, MU, RCII]

Vessix Vascular has developed a catheter-based renal denervation system for the treatment of uncontrolled hypertension. Boston Scientific said renal denervation represents a potential breakthrough therapy for the treatment of uncontrolled hypertension and is an important part of the company's growth strategy.

"The acquisition of Vessix Vascular adds a second generation, highly differentiated technology to our hypertension strategy while accelerating our entry into what we expect to be a multi-billion dollar market by 2020," said Mike Mahoney, chief executive at Boston Scientific.

Upon completion of the acquisition, Vessix Vascular will become part of the Peripheral Interventions business at Boston Scientific. The portfolio of this business includes products that treat vascular system blockages in areas such as the carotid and renal arteries and the lower extremities.

[Related -Top Insider Purchases: BSX, CLMS, GNW, OPK, PBI, SPB]

Renal denervation is an emerging, catheter-based therapy for medication-resistant hypertension that uses radio-frequency energy to disrupt the renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.

The Vessix Vascular V2 Renal Denervation System has received CE Mark in Europe and TGA approval in Australia. Vessix Vascular has initiated the REDUCE-HTN post-market surveillance study and expects to initiate a full launch of the product in CE Mark countries in 2013.

The V2 Renal Denervation System is an investigational device and not available for use or sale in the United States. The acquisition is expected to close by the end of November 2012.

BSX is trading down 0.19 percent at $5.15 on Thursday. The stock has been trading between $4.79 and $6.41 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageLadenburg Thalmann Financial Services (NYSEMKT:LTS): Heavy, Durable Insider Buying

Ahh, but any worries over price levels didn’t stop multiple insiders at Ladenburg Thalmann Financial read on...

article imageInternational Business Machines Corp. (IBM) Q2 Earnings Preview: Small Beat and Pop

International Business Machines Corp. (NYSE:IBM) will host a conference call Wednesday, Jul. 16, 2014 at read on...

article imageGoogle Inc. (GOOGL) Q2 Earnings Preview: A Few Pennies Either Way Make a Big Difference.

Google Inc. (NASDAQ:GOOGL) will hold its quarterly conference call to discuss second quarter 2014 financial read on...

article image19 Companies That Could Beat Earnings and Pop on Price Next Week

Using iStock’s proprietary iEstimates model, we have identified 19 publicly traded companies that could read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.